Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
New Horizons and Surgical Decision Making in HPB Cancer
share announcement

New Horizons and Surgical Decision Making in HPB Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 4064

Special Issue Editors

Dr. Stefano Granieri

E-Mail Website
Guest Editor
General Surgery Unit, ASST-Brianza, Vimercate Hospital, Via Santi Cosma e Damiano 10, 20871 Vimercate, Italy
Interests: surgical oncology; trauma and acute care surgery; HPB surgery; upper and lower GI surgery
Dr. Christian Cotsoglou

E-Mail Website
Guest Editor
General Surgery Unit, ASST-Brianza, Vimercate Hospital, Via Santi Cosma e Damiano 10, 20871 Vimercate, Italy
Interests: surgical oncology; hepatobiliary surgery; pancreatic surgery; upper and lower GI surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

To date, surgery represents the key treatment of most hepatobiliary and pancreatic (HPB) cancers. One of the biggest challenges of modern medicine is to apply technology to deliver the best care service to patients. Advances in the medical field have provided new opportunities to support surgeons in performing surgical procedures and to enhance patient benefits and safety.

The present Special Issue will mainly focus on new technologies currently used in the field of HPB surgery and new emerging ones that may help drive surgical decision-making. We further aim to inspire, inform, and provide both direction and guidance to surgeons and researchers in the field.

We strongly encourage authors to submit high-quality research articles focusing on emerging surgical strategies and innovative technologies for the management of HPB diseases.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: Original articles as well as review articles, and meta-analyses.

We look forward to receiving your contributions.

Dr. Stefano Granieri
Dr. Christian Cotsoglou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatobiliary and pancreatic cancers
  • HPB surgery
  • technological advances
  • 3D technologies
  • artificial intelligence
  • innovative technologies
  • meta-analyses

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

21 pages, 579 KiB  
Review
The Current Role of Radiation in the Management of Cholangiocarcinoma—A Narrative Review
by Saurav Verma, Natalie Grindrod, Daniel Breadner and Michael Lock
Cancers 2024, 16(9), 1776; https://doi.org/10.3390/cancers16091776 - 4 May 2024
Viewed by 1018
Abstract
Cholangiocarcinoma (CCA) is a rare cancer of bile ducts. It is associated with a poor prognosis. The incidence of CCA is rising worldwide. Anatomical subgroups have been used to classify patients for treatment and prognosis. There is a growing understanding of clinically important [...] Read more.
Cholangiocarcinoma (CCA) is a rare cancer of bile ducts. It is associated with a poor prognosis. The incidence of CCA is rising worldwide. Anatomical subgroups have been used to classify patients for treatment and prognosis. There is a growing understanding of clinically important distinctions based on underlying genetic differences that lead to different treatment options and outcomes. Its management is further complicated by a heterogeneous population and relative rarity, which limits the conduct of large trials to guide management. Surgery has been the primary method of therapy for localized disease; however, recurrence and death remain high with or without surgery. Therefore, there have been concerted efforts to investigate new treatment options, such as the use of neoadjuvant treatments to optimize surgical outcomes, targeted therapy, leveraging a new understanding of immunobiology and stereotactic radiation. In this narrative review, we address the evidence to improve suboptimal outcomes in unresectable CCA with radiation, as well as the role of radiation in neoadjuvant and postoperative treatment. We also briefly discuss the recent developments in systemic treatment with targeted therapies and immune checkpoint inhibitors. Full article
(This article belongs to the Special Issue New Horizons and Surgical Decision Making in HPB Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Review

16 pages, 2761 KiB  
Systematic Review
Short-Term Outcomes after D2 Gastrectomy with Complete Mesogastric Excision in Patients with Locally Advanced Gastric Cancer: A Systematic Review and Meta-Analysis of High-Quality Studies
by Stefano Granieri, Annaclara Sileo, Michele Altomare, Simone Frassini, Elson Gjoni, Alessandro Germini, Alessandro Bonomi, Eigo Akimoto, Chun Lam Wong and Christian Cotsoglou
Cancers 2024, 16(1), 199; https://doi.org/10.3390/cancers16010199 - 31 Dec 2023
Viewed by 1035
Abstract
Complete mesogastric excision (CME) has been advocated to allow for a more extensive retrieval of lymph nodes, as well as lowering loco-regional recurrence rates. This study aims to analyze the short-term outcomes of D2 radical gastrectomy with CME compared to standard D2 gastrectomy. [...] Read more.
Complete mesogastric excision (CME) has been advocated to allow for a more extensive retrieval of lymph nodes, as well as lowering loco-regional recurrence rates. This study aims to analyze the short-term outcomes of D2 radical gastrectomy with CME compared to standard D2 gastrectomy. A systematic review of the literature was conducted according to the Cochrane recommendations until 2 July 2023 (PROSPERO ID: CRD42023443361). The primary outcome, expressed as mean difference (MD) and 95% confidence intervals (CI), was the number of harvested lymph nodes (LNs). Meta-analyses of means and binary outcomes were developed using random effects models to assess heterogeneity. The risk of bias in included studies was assessed with the RoB 2 and ROBINS-I tools. There were 13 studies involving 2009 patients that were included, revealing a significantly higher mean number of harvested LNs in the CME group (MD: 2.55; 95% CI: 0.25–4.86; 95%; p = 0.033). The CME group also experienced significantly lower intraoperative blood loss, a lower length of stay, and a shorter operative time. Three studies showed a serious risk of bias, and between-study heterogeneity was mostly moderate or high. Radical gastrectomy with CME may offer a safe and more radical lymphadenectomy, but long-term outcomes and the applicability of this technique in the West are still to be proven. Full article
(This article belongs to the Special Issue New Horizons and Surgical Decision Making in HPB Cancer)
►▼ Show Figures

Figure 1

12 pages, 9081 KiB  
Systematic Review
The Role of Non-Peripancreatic Lymph Nodes in the Survival of Patients Suffering from Pancreatic Cancer of the Body and Tail: A Systematic Review and Meta-Analysis of High-Quality Studies
by Stefano Granieri, Alessia Kersik, Alessandro Bonomi, Simone Frassini, Davide Bernasconi, Sissi Paleino, Alessandro Germini, Elson Gjoni and Christian Cotsoglou
Cancers 2023, 15(8), 2322; https://doi.org/10.3390/cancers15082322 - 16 Apr 2023
Cited by 1 | Viewed by 1617
Abstract
Lymph nodes (LNs)’ metastases have a well-known detrimental impact on the survival outcomes of patients suffering from pancreatic cancer of the body and tail. However, the extent of the lymphadenectomy for this tumor location is still debated. The aim of this study was [...] Read more.
Lymph nodes (LNs)’ metastases have a well-known detrimental impact on the survival outcomes of patients suffering from pancreatic cancer of the body and tail. However, the extent of the lymphadenectomy for this tumor location is still debated. The aim of this study was to systematically review the current literature to explore the incidence and the prognostic impact of non-peripancreatic lymph nodes (PLNs) in patients suffering from pancreatic cancer of the body and tail. A systematic review was conducted according to PRISMA and MOOSE guidelines. The primary endpoint was to assess the impact of non-PLNs on overall survival (OS). As a secondary endpoint, the pooled frequencies of different non-PLN stations’ metastatic patterns according to tumor location were explored. Eight studies were included in data synthesis. An increased risk of death for patients with positive non-PLNs was detected (HR: 2.97; 95% CI: 1.81–4.91; p < 0.0001). Meta-analysis of proportions pointed out a 7.1% pooled proportion of nodal infiltration in stations 8–9. The pooled frequency for station 12 metastasis was 4.8%. LN stations 14–15 were involved in 11.4% of cases, whereas station 16 represented a site of metastasis in 11.5% of cases. Despite its potential beneficial effect on survival outcome, a systematic extended lymphadenectomy could not be recommended yet for patients suffering from PDAC of the body/tail. Full article
(This article belongs to the Special Issue New Horizons and Surgical Decision Making in HPB Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop